Business ❯ Corporate Law ❯ Regulatory Compliance

FDA Regulations

Clinical Trials Facility Inspections New Drug Application

Cytokinetics Investors Face Nov. 17 Deadline to Seek Lead Role in Aficamten Securities Case

The pending Northern District of California lawsuit alleges the company misled investors by filing its aficamten NDA without a REMS after FDA discussions, affecting the expected review timeline.

4 ARTICLES

2mo ago

FDA Regulations

Cytokinetics Investors Face Nov. 17 Deadline to Seek Lead Role in Aficamten Securities Case

Investor Firms Urge Cytokinetics Shareholders to Seek Lead Role in FDA-Disclosure Suit Before Nov. 17